TYMS was identified as a biomarker for hepatocellular carcinoma liver transplantation, pancreatic and colorectal cancer (Zhang et al., 2016; Ntavatzikos et al., 2017; Fu et al., 2019). This evidence concerns the gene TYMS and hepatocellular carcinoma.